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Background/aim: Neural tube defects (NTDs) are common congenital malformations that develop as a result of interactions between
several genes and environmental factors. Many factors have been investigated in order to understand the etiology of NTDs, and many
studies have identified folate intake as a common contributing factor. The exact etiology of the disease is still unknown.
Materials and methods: In this study, we compared serum folate, vitamin B12, and homocysteine levels, along with common
thrombophilia-related genetic variations, including factor V Leiden, factor II g.20210G>A, MTHFR c.677C>T, and MTHFR c.1298A>C,
in 35 pregnant women with fetal NTDs and 38 pregnant women with healthy fetuses.
Results: A significant difference in serum vitamin B12 level and factor V Leiden frequency was detected between the two groups. On
the other hand, serum folate, homocysteine levels, and factor II g.20210G>A, MTHFR c.677C>T, and MTHFR c.1298A>C were not
significantly different in the NTD group compared to the controls.
Conclusion: These results indicate that vitamin B12 supplementation along with folate may help in lowering NTD frequency. In
addition, this is the first study that provides evidence for a possible relationship between increased NTD risk and factor V Leiden.
Key words: Folate, vitamin B12, homocysteine, thrombophilia, neural tube defects

1. Introduction
Neural tube defects (NTDs) are a spectrum of defects
that arise as a result of nonclosure of the neural tube until
6 weeks of gestation (1). They are frequent congenital
malformations affecting 0.5–2 per 1000 pregnancies (2).
Several types of NTDs are recognized. Major types include
acrania, anencephaly, spina bifida, craniorachischisis,
encephalocele, and inencephaly. These defects are caused
by multiple factors involving genetic predisposition and by
environmental factors such as nutritional deficiencies and
drug exposure (2).
Despite the fact that more than 200 genes are known
to cause NTDs in rats, human studies have been limited
in identifying the underlying molecular genetic basis.
An association has been found between NTDs and
5,10-methylene-tetrahydrofolate reductase (MTHFR)
variations, which lead to defective homocysteine
metabolism. It has been shown that supplementation
* Correspondence: dr.hatip@gmail.com

of folate and vitamin B12, which are coenzymes in the
homocysteine metabolic pathway, is effective in reducing
the risk of NTDs (3). Similar to MTHFR variations,
factor V Leiden and factor II g.20210G>A variations also
predispose to thrombophilia. However, these variations
have not been associated with NTD risk.
Intake of folate during pregnancy is widely advised
in Turkey. In order to demonstrate the importance
of predisposing factors in the Turkish population, we
investigated the effects of previously known and suspected
factors in the etiology of NTDs. For this purpose, serum
levels of folate, vitamin B12, and homocysteine, as well
as genetic variations including factor V Leiden, factor II
g.20210G>A, MTHFR c.677C>T, and MTHFR c.1298A>C,
were determined in pregnant Turkish women with fetal
NTDs and in healthy pregnant women in order to point
out significant differences.
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2. Materials and methods
2.1. Subjects
Pregnant women with fetal NTDs and the controls were
retrospectively evaluated at the Zeynep Kamil Women’s
and Children’s Diseases Training and Research Hospital,
İstanbul, Turkey. Thirty-five pregnant women with fetal
NTDs between 14 and 24 weeks of gestation constituted
the NTD group. The diagnosis of NTD was confirmed
after termination or delivery for each subject. The NTD
group was made up of women who had isolated fetal
spina bifida or craniorachischisis and no maternal chronic
diseases. Pregnant women were included in the NTD
group regardless of their folate usage during pregnancy.
The control group consisted of 40 unrelated individuals
applying for different reasons. Women in the control group
were observed throughout their pregnancies and did
not have any maternal chronic diseases, fetal karyotype
anomalies, or multiple gestations, and their pregnancies
were not complicated by intrauterine growth retardation
or polyhydramnios. The children born to women in the
control group had a birth weight between the 10th and the
90th percentile.
Each woman was followed with regular ultrasound
evaluations, which were obtained transabdominally
using an abdominal 2–5 MHz curvilinear transducer
(Voluson, General Electric, Milwaukee, WI, USA). In
each ultrasound evaluation, biparietal diameter, head and
abdominal circumference, and femur and humerus length
were measured in the standard planes for fetal biometric
evaluation, and a routine scan of fetal anatomy was
performed.
Serum homocysteine levels (Abbott IMx Fluorescence
Polarization Immunoassay, USA), serum folate (Abbott
Architect Folate, USA), and vitamin B12 (Abbott Architect
B12, USA) were quantified according to the manufacturer’s
protocol. Measurements were made with the Abbott
Architect i1000 Immunoassay Analyzer.
Homocysteine 
levels in 10 women, vitamin B12
levels in 1 woman, and folate levels in 2 women from the
NTD group were not present in their medical records. In
addition, homocysteine levels

in 7 women, vitamin B12
levels in 3 women, and folate levels in 3 women from the
control group were not present in their medical records.
2.2. Genotyping
Genomic DNA was isolated from peripheral blood
leukocytes using the Magnesia DNA Blood Kit (Anatolia
Inc., Turkey). Factor V Leiden, factor II g.20210G>A,
MTHFR c.677C>T, and MTHFR c.1298A>C variations
were genotyped using the Bosphore Kit and real-time PCR
with Montania 483 (Anatolia Inc., Turkey), according to
the guidelines of the manufacturer.
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2.3. Statistical analysis
Statistical analyses were performed using SPSS 16.0 (SPSS
Inc., Chicago, IL, USA). The chi-square test was employed
to compare allele frequencies and genotypes for factor
V Leiden, factor II g.20210G>A, MTHFR c.677C>T,
and MTHFR c.1298A>C between pregnant women with
fetal NTDs and the control group. The Wilcoxon W and
Mann–Whitney U tests were employed to compare serum
homocysteine, folate, and vitamin B12 levels between
groups. Statistical significance was established at P < 0.05.
3. Results
There were no known factors in patient history associated
with NTDs, such as exposure to radiation, maternal
anticonvulsant or chemical substance usage, and diabetes
mellitus. The mean age of the pregnant women was 28
years (range: 20–39) and 30 years (range: 22–35) in the
NTD group and control group, respectively. The mean
gestational week of women in the NTD group was 18
weeks (range: 14–24), whereas that of women in the
control group was 19 weeks (range: 16–23). There was no
significant difference in maternal age or gestational week
between groups (P = 0.207).
According to our data, factor II g.20210G>A, MTHFR
c.677C>T, and MTHFR c.1298A>C genotype frequencies
in the NTD group were similar to those of the controls
(P = 0.521, P = 0.706, and P = 0.405, respectively) (Table
1). However, factor V Leiden genotype frequency was
significantly higher in the NTD group than in the control
group (P = 0.029, 95% CI = [0.014137–1.086414], odds
ratio = 0.123932) (Table 1).
Additionally, there was a significant difference in serum
vitamin B12 levels between groups (P = 0.006) (Table 2).
On the other hand, serum folate and homocysteine levels
were not significantly higher in the NTD group compared
to the controls (P = 0.223 and P = 0.115, respectively)
(Table 2).
4. Discussion
NTDs are among the most common birth defects. They
are defects of the spinal cord or brain that result from
failure of neural tube closure in the early stages of fetal
development (2).
NTDs are multifactorial disorders with many genetic
and environmental factors defined in their etiology.
Chromosomal abnormalities can cause NTDs, although
these represent only 2%–16% of isolated NTDs (4). Women
bearing fetuses with chromosomal abnormalities were
excluded from this study in order to prevent differences
between NTD and control groups that may arise as a result
of different chromosomal backgrounds.
Folate cycles between molecules in certain biological
reactions carry one-carbon groups from other molecules
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Table 1. The distribution of genotype frequencies and P values between NTD mothers
and controls.
Genotype

Patients

Controls

FV c.1691GG

29/35 (82.9%)

39/40 (97.5%)

FV c.1691GA

6/35 (17.1%)

1/40 (2.5%)

FV c.1691AA

0/35 (0%)

0/40 (0%)

P-value

0.029

FII g.20210GG

35/35 (100%)

37/40 (97.5%)

FII g.20210GA

0/35 (0%)

1/40 (2.5%)

FII g.20210AA

0/35 (0%)

0/40 (0%)

P-value

0.521

MTHFR c.677CC

16/35 (40.0%)

15/40 (39.5%)

MTHFR c.677CT

16/35 (42.5%)

21/40 (52.6%)

MTHFR c. 677TT

3/35 (7.5%)

3/40 (7.9%)

P-value

0.706

MTHFR c.1298AA

16/35 (45.7%)

13/36 (36.1%)

MTHFR c.1298AC

15/35 (42.9%)

17/36 (47.2%)

MTHFR c.1298CC

4/35 (11.4%)

6/36 (16.7%)

P-value

0.405

Table 2. The means and standard deviations of homocysteine, folate, and vitamin B12 levels and P-values between NTD
mothers and controls.
Genotype

Homocysteine (µmol/L)

Folate (ng/mL)

Vitamin B12 (pg/mL)

Patients

6.7 ± 1.7 (25 cases)

14.7 ± 7.0 (33 cases)

220 ± 67 (34 cases)

Control

6.0 ± 1.6 (33 cases)

18.1 ± 9.9 (37 cases)

260 ± 64 (37 cases)

P-value

0.115

0.223

0.006

to homocysteine in order to form methionine. This
folate cycle is a vital biochemical reaction required for
proper DNA synthesis, repair, and methylation. Thus,
low folate levels can directly limit its availability to cells
or indirectly disrupt methionine metabolism, thereby
increasing homocysteine. MTHFR can influence
serum homocysteine levels, especially in inadequacy of
folate. Increased homocysteine and MTHFR variations
play significant roles in NTD. Additionally, both folate and
vitamin B12 insufficiency can contribute to increased risk
of NTDs. As previously shown, folate given before and
during the first 4 weeks of pregnancy can prevent 50%
or more of NTDs. Folate availability is thought to play

an important role in phenotypic expression of MTHFR
mutations (5–7).
Vitamin B12 is also an important factor in folate
metabolism. A previous study has shown that vitamin
B12 deficiency also contributes to the risk of NTDs (8).
When vitamin B12 levels are low, the resulting decrease
in methylation activity is thought to account for some
of the deleterious effects of vitamin B12 deficiency in
fetal development (9). In a previous study, lower levels
of maternal vitamin B12 were linked to higher NTD
occurrence, and authors argued that supplementing
vitamin B12 with folate during pregnancy may further
decrease NTD risk in the fetus (10).
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In accordance with their common involvement in
the same metabolic pathway, many previous studies have
also found a relationship between maternal serum folate,
vitamin B12, and homocysteine levels and NTD risk in
humans. In a study of 107 pregnant women with NTDs and
275 controls, Cech et al. reported that median folate and
vitamin B12 levels for the NTD group were significantly
lower than for the controls (11). In another study by
Zhang et al. comparing 82 women with fetal NTDs and
110 controls, a relation between increased risk of NTDs
and lower serum levels of folate and vitamin B12 was
shown (12). In a study of a different group, homocysteine
and vitamin B12 levels were significantly different in
the NTD group compared to the controls, whereas the
median serum folate levels were similar. In this study,
lower maternal serum vitamin B12 levels were associated
with an approximately 2- to 3-fold increase in NTD risk
(13). According to Gu et al. (14), homocysteine levels
were significantly higher in the NTD group than in the
control group, with an accompanying lower serum folate
and vitamin B12 level in the NTD group. In a study of
homocysteine in 103 cases and 139 controls, high serum
levels were associated with NTD pregnancies. According
to this study, high homocysteine levels have a deleterious
effect on proper neural tube closure, even when serum
vitamin B12 or folate levels are high (15).
On the contrary, several other studies have questioned
this relationship. In two different investigations, Greene et
al. (16) and Bennett et al. (17) reported that an increase
in NTD incidence was not observed in mouse embryos
exposed to high levels of homocysteine. Mobasheri et al.
(18) reported that levels of folate and vitamin B12 did
not significantly affect NTD risk in 23 women with NTD
fetuses and 23 healthy controls. Ceyhan et al. (19) carried
out a study similar to ours on 31 pregnant women with
fetal NTDs and 32 controls with healthy fetuses. In their
study, no relation was shown between vitamin B12 levels
and NTDs.
In our study, significantly lower maternal serum
vitamin B12 levels (220 ± 67 vs. 260 ± 64; P = 0.006)
was found in pregnancies with fetal NTDs compared
to controls. However, we did not observe a significant
difference between serum folate and homocysteine levels.
Previously, many studies reported a significant difference
in maternal folate and homocysteine levels between NTD
pregnancies and controls, which was not the case in our
study. The reason for this may be the supplementation of
folate before pregnancy in our study population.
This study shows that folate supplementation alone is
not sufficient for the prevention of NTDs. In addition to
folate, supplementation of vitamin B12 may lower NTD
risk more efficiently. However, vitamin B12 levels were not
low in the entire NTD group, which suggests that factors
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other than lack of vitamin B12 are also important for
increased NTD risk. Future investigations to determine
the contribution of other coenzymes and cofactors
affecting methionine-homocysteine metabolism to NTD
risk might help us understand NTD pathogenesis in more
detail and provide us with additional dietary tools to allow
for a decrease in NTD risk.
Among folate metabolism-related genes, MTHFR has
been the principal focus of attention. Previous studies have
shown that the c.677C>T and c.1298A>C variations are
associated with increased risk of NTDs (20,21). Studies also
suggest that the c.677TT genotype confers a 2- to 3-fold
increased risk of NTDs (20,22). The c.1298A>C variation
is also a risk factor for NTDs, though with a smaller
contribution compared to c.677C>T variation. Indeed,
the frequency of the c.1298A>C variation in children with
NTD tends to be increased, which also suggests that this
mutation is a genetic risk factor (23).
Another study by Liu et al. (24) showed that MTHFR
c.677C>T variation was significantly higher in the tissue or
blood samples of 609 aborted fetuses with NTD compared
to 1106 parental blood samples as controls. However,
this study failed to show any significant effect of folate
supplementation and gestational diabetes mellitus on NTD
occurrence (24). In a similar study, 51 women who had
children with NTDs had a significantly different genotype
distribution for MTHFR c.677C>T variation compared to
51 age-matched women with healthy children (25).
In a study from Turkey, Boduroğlu et al. (26) reported
that the MTHFR c.1298AA/c.677TT genotype was
significantly more frequent in 95 children with NTDs than
in the 93 healthy controls.
On the other hand, Candito et al. (27) reported that
MTHFR c.677C>T and c.1298A>C variations were not
associated with increased NTD risk in fetuses, following
the comparison of 77 women with severe fetal NTDs and
61 women with normal pregnancies.
In this study, frequencies of MTHFR c.677C>T and
c.1298A>C variations did not differ significantly between
NTD and control groups. This shows that these variations
in pregnant women do not confer an increased fetal NTD
risk in our study population.
Factor V Leiden variation is an important risk factor
for hereditary thrombophilia. Thrombophilia-related
conditions such as thromboembolism and deep vein
thrombosis have also been associated with factor V Leiden.
However, Ceyhan et al. showed no relationship between
factor V Leiden or factor II g.20210G>A variations and
spina bifida. On the other hand, they suggested that the
presence of MTHFR c.677C>T variation increased the risk
of spina bifida (28). In our study, factor II g.20210G>A,
MTHFR c.677C>T, and c.1298A>C are not significantly
related with NTDs, whereas factor V Leiden variation
significantly increased the risk of NTDs.
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To the best of our knowledge, this is the first study
showing a possible relationship between factor V Leiden
variation and NTD risk. A possible mechanism that can
explain the increased risk of NTDs in factor V Leidencarrying mothers may be insufficient nourishment of the
fetus during critical stages of development and closure
of the neural tube due to placental insufficiency. It has
been shown previously that genetic thrombophilia causes
placental insufficiency resulting in intrauterine growth
retardation (29). In addition, it has been reported that
mothers with factor V Leiden variation are more prone
to having children with fetal ischemia-related conditions
such as cerebral palsy or perinatal arterial ischemic stroke
(30,31). However, further investigation is needed to show

that increased NTD risk for factor V Leiden variation
carriers found in this study is not coincidental, and to
establish a causal link explaining this relationship. Lack of
association between factor II and NTDs may be due to the
very small number of patients with factor II g.20210G>A
in the study.
As the result of this study, we suggest that intake of folate
alone is not sufficient in the prevention of NTDs; instead,
folate intake of vitamin B12 is also important. A dietary
supplement combining folate and vitamin B12 might be an
effective measure to decrease the NTD incidence in these
areas. Moreover, further investigations are required for
identifying the interaction between factor V Leiden and
NTDs.
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